Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

155953

	registered interest
	date	17/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Drugs: Licensing
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will set targets and goals for speeding up the use of off-patent drugs outside their licensed indications, where evidence supports that use.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	214424
	answer	answer is ministerial correction date of answer 24/11/2014 answer text <p>We have no plans to set such targets or goals.</p><p> </p><p> </p><p> </p><p>Off-patent drugs are those whose patent period has expired and they are widely used in the National Health Service now. Drugs can also be prescribed ‘off-label’ outside of their licensed indication(s) to individual patients where doctors consider it is clinically appropriate to do so. Prescribing decisions are rightly a matter for clinicians in discussion with their patients.</p><p> </p><p> </p><p> </p><p>We are in the process of setting up a round-table discussion with key stakeholders, including NHS England and the National Institute for Health and Care Excellence to explore opportunities for supporting appropriate use of off-label drugs outside their licensed indications where the evidence supports this.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 24/11/2014 17:35:43 answering member 4020 label Biography information for George Freeman
	tabling member	3960 label Biography information for Henry Smith

93569

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he plans to take to protect the future of local breast network groups should his Department's proposal for discontinuing the National Cancer Peer Review programme from 2015 go ahead.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	210723
	answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>The National Cancer Peer Review (NCPR) programme is currently under review by NHS England and a number of options are being considered. The provision of site specific networks, such as those for breast cancer, is written into the national cancer peer review requirements, therefore the future of local breast network groups will be decided as part of the review of the NCPR programme. As yet however, no decision has been made.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 210989 question first answered 22/10/2014 15:15:00 answering member 3918 label Biography information for Jane Ellison
	tabling member	3960 label Biography information for Henry Smith

78022

	registered interest
	date	15/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Respiratory System: Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps (a) his Department and (b) NHS England plan to take to reduce premature mortality from respiratory disease.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	205718
	answer	answer is ministerial correction date of answer 22/07/2014 answer text <p>The NHS Outcomes Framework 2014-15 sets out the Department’s priority areas for the National Health Service and includes reducing deaths from respiratory disease as a key indicator. In addition to this, the Mandate sets out the requirements for NHS England to improve outcomes in a range of areas, including preventing premature deaths from the biggest killers (including respiratory) and supporting people with long term physical and mental health conditions.</p><p> </p><p><em>Living Well for Longer: National Support for Local Action to Reduce Premature Mortality</em>, launched in April, sets out what the health and care system will do to achieve the Government’s ambition to be amongst the best in Europe at reducing levels of premature mortality. It brings together in one place the national actions taken by the Department of Health and wider Government, NHS England and Public Health England, in prevention, early diagnosis and treatment, focusing on the five big killers, including lung disease, and shows how they will support local leadership and interventions.</p><p> </p><p>The Department has supported a number of initiatives to help improve outcomes for people with respiratory disease. In July 2011, it published an outcomes strategy for people with chronic obstructive pulmonary disease (COPD) and asthma in England, which sets out six high-level objectives to improve outcomes in these areas through high quality prevention, detection, treatment and care services. The Department has also supported the publication of a good practice guides on services for adults with asthma, which was published in 2012.</p><p> </p><p>The National Institute for Health and Care Excellence has published Quality Standards for COPD and for asthma setting out the markers of high-quality, cost-effective care and the implementation of these will also raise the standard of care people with these conditions receive.</p><p> </p><p>The Department has collaborated with the National Review of Asthma Deaths which is examined the circumstances surrounding deaths from asthma from 1 February 2012 to 30 January 2013 and reported on its findings in May of this year. Lessons learnt about the factors that contribute to asthma deaths will inform the NHS about what constitutes good care, and encourage the development of appropriate services for people with asthma.</p><p> </p><p>Public Health England recently ran a local pilot campaign in Oldham and Rochdale to raise awareness amongst the public about the importance of visiting their general practitioner with symptoms of breathlessness.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 22/07/2014 14:13:24 answering member 3918 label Biography information for Jane Ellison
	tabling member	3960 label Biography information for Henry Smith

174759

	registered interest
	date	20/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Bile Duct Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what research his Department has commissioned into cholangiocarcinoma.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	221396
	answer	answer is ministerial correction date of answer 27/01/2015 answer text <p>The Department has not commissioned any research relating specifically to cholangiocarcinoma. The National Institute for Health Research Imperial Biomedical Research Centre has a £3.6 million gastroenterology and hepatology research theme (2012-17). This includes research on cholangiocarcinoma biomarkers and imaging.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/01/2015 12:35:01 answering member 4020 label Biography information for George Freeman
	tabling member	3960 label Biography information for Henry Smith

155948

	registered interest
	date	17/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to encourage flexibility in the licensing process for potential new treatments for rare conditions.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	214491
	answer	answer is ministerial correction date of answer 24/11/2014 answer text <p>Most new medicines for rare conditions are licensed by the European Commission.</p><p> </p><p>The European Union offers a range of incentives to encourage the development of these medicines in order to address unmet clinical need. These incentives include a period of 10 years market exclusivity, the provision of Protocol Assistance (scientific advice specifically tailored for orphan medicinal products) and fee reductions and waivers for regulatory procedures.</p><p> </p><p> </p><p> </p><p>Through the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom takes an active role in the decision making process at the European Medicines Agency’s Committee on Orphan Medicinal Products, ensuring applications for Orphan Drug designation of potential drug candidates for rare diseases are appropriately recognised, encouraging companies to develop their products further and recommending use of existing flexibilities such as conditional authorisation, authorisation under exceptional circumstances and accelerated assessment. The UK is actively involved in the European Medicines Agency’s adaptive licensing pilot that is exploring further use of these flexibilities. The MHRA has an Innovation Office that can offer advice and assistance to developers of drugs for rare diseases, including on the use of flexibilities.</p><p> </p><p><strong> </strong></p><p> </p><p>In addition, in the UK, the Early Access to Medicines Scheme aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need.</p><p> </p><p> </p><p> </p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 24/11/2014 17:23:13 answering member 4020 label Biography information for George Freeman
	tabling member	3960 label Biography information for Henry Smith

92614

	registered interest
	date	10/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hives
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many people in England have been diagnosed with chronic spontaneous urticaria in each year since 2010.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	209936
	answer	answer is ministerial correction date of answer 17/10/2014 answer text <p>Information concerning the number of people with chronic spontaneous urticaria (also known as hives, welts or nettle rash) in England is not collected. However, the National Institute for Health and Care Excellence estimates that approximately 15% of people in the United Kingdom experience urticaria at some time in their lives and the lifetime prevalence of chronic urticaria is 0.5–1%.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 209937 question first answered 17/10/2014 12:05:07 answering member 1439 label Biography information for Norman Lamb
	tabling member	3960 label Biography information for Henry Smith

92615

	registered interest
	date	10/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hives
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many people have chronic spontaneous urticaria in England.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	209937
	answer	answer is ministerial correction date of answer 17/10/2014 answer text <p>Information concerning the number of people with chronic spontaneous urticaria (also known as hives, welts or nettle rash) in England is not collected. However, the National Institute for Health and Care Excellence estimates that approximately 15% of people in the United Kingdom experience urticaria at some time in their lives and the lifetime prevalence of chronic urticaria is 0.5–1%.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 209936 question first answered 17/10/2014 12:05:07 answering member 1439 label Biography information for Norman Lamb
	tabling member	3960 label Biography information for Henry Smith

105961

	registered interest
	date	03/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Bowel Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the results of pilots of flexible sigmoidoscopy screening for bowel cancer; and what plans he has for a nationwide rollout of such screening.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	212890
	answer	answer is ministerial correction date of answer 10/11/2014 answer text <p>A randomised controlled trial funded by Cancer Research UK, the Medical Research Council and National Health Service Research and Development took place in 14 United Kingdom and six Italian centres, and evaluated screening for bowel cancer using a single Bowel Scope Screening (flexible sigmoidoscopy) between 55 and 64 years of age, removing small polyps by Bowel Scope Screening and providing full colonoscopy for &quot;high risk&quot; polyps. The study concluded that Bowel Scope Screening is a safe and practical test and, when offered only once between ages 55 and 64 years, confers a substantial and long lasting benefit. The UK National Screening Committee reviewed the evidence, and in April 2011 concluded that screening for bowel cancer using Bowel Scope Screening meets the United Kingdom National Screening Committee criteria for a screening test. In England its implementation will be managed by National Health Service Cancer Screening Programmes.</p><p> </p><p> </p><p> </p><p>As at 31 March 2014, 36.6% of Bowel Scope Screening centres in England were operational, exceeding the commitment of 30%<sup>1</sup>. As set out in the third annual report of <em>Improving Outcomes: A Strategy for Cancer</em> (December 2013), NHS England will work with Public Health England to help deliver the involvement of screening centres sufficient to meet the 60% commitment by March 2015 and to support preparatory steps in other screening centres to implement by the end of 2016.</p><p> </p><p> </p><p> </p><p>As at the end of October 2014, 20,603 examinations had taken place. 919 people had gone on to have a colonoscopy with 20 cancers being detected. A further 365 people have had an advanced adenoma found and removed.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p>[1] <a href="https://www.gov.uk/government/news/latest-bowel-cancer-screening-technique-reaps-benefits" target="_blank">https://www.gov.uk/government/news/latest-bowel-cancer-screening-technique-reaps-benefits</a></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/11/2014 17:54:15 answering member 3918 label Biography information for Jane Ellison
	tabling member	3960 label Biography information for Henry Smith